CMAP Plus Trauma-focused Cognitive Behavior Therapy for Suicidal Ideation Among Burn Survivors
Launched by PAKISTAN INSTITUTE OF LIVING AND LEARNING · Jul 7, 2022
Trial Information
Current as of September 08, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called CMAP Plus Trauma-focused Cognitive Behavior Therapy (TFBCT) for Suicidal Ideation Among Burn Survivors, is designed to explore a new therapy aimed at helping burn survivors who are experiencing thoughts of suicide. The researchers want to find out if this therapy is easy to access and acceptable for people in this situation. They will also look at any challenges in getting participants to join the study and collect some initial information that can help plan a larger trial in the future.
To be eligible for this study, participants must be at least 18 years old, have experienced a burn injury, and have been identified as having suicidal thoughts using a specific assessment tool. It's important that they can give permission to participate and live near the hospitals involved in the study. Unfortunately, people who can’t provide consent due to serious health issues or those who may not be available for follow-up assessments won’t be included. If someone joins the trial, they can expect to engage in therapy sessions designed to help them cope with their feelings and improve their well-being. The trial is not yet recruiting participants, but it aims to provide valuable insight into supporting burn survivors facing these challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18 and above
- • Had burn injury and identified for having suicidal ideation measures with Beck scale for suicidal Ideation (BSI)
- • Able to give informed consent
- • Living within the catchment areas of participating hospitals
- Exclusion Criteria:
- • Unable to provide consent due to severe mental or physical illness
- • Unlikely to be available for outcome assessments (temporary residence)
About Pakistan Institute Of Living And Learning
The Pakistan Institute of Living and Learning (PILL) is a leading clinical trial sponsor dedicated to advancing healthcare through innovative research and evidence-based practices. With a focus on improving mental health and overall well-being, PILL conducts rigorous clinical trials that aim to evaluate new treatments and therapeutic approaches. The institute collaborates with a diverse range of stakeholders, including healthcare professionals, researchers, and community organizations, to ensure the highest standards of ethical conduct and scientific integrity in its studies. PILL is committed to translating research findings into practical solutions that enhance the quality of life for individuals and communities in Pakistan and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials